4uva: Difference between revisions
m Protected "4uva" [edit=sysop:move=sysop] |
No edit summary |
||
| Line 1: | Line 1: | ||
''' | ==LSD1(KDM1A)-CoREST in complex with 1-Methyl-Tranylcypromine (1R,2S)== | ||
<StructureSection load='4uva' size='340' side='right' caption='[[4uva]], [[Resolution|resolution]] 2.90Å' scene=''> | |||
== Structural highlights == | |||
<table><tr><td colspan='2'>[[4uva]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4UVA OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4UVA FirstGlance]. <br> | |||
</td></tr><tr><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=D73:[(2R,3S,4R,5R)-5-(6-AMINO-9H-PURIN-9-YL)-3,4-DIHYDROXYTETRAHYDROFURAN-2-YL]METHYL+(2R,3S,4S)-2,3,4-TRIHYDROXY-5-[(4AS)-4A-[(1S,3E)-3-IMINO-1-PHENYLBUTYL]-7,8-DIMETHYL-2,4-DIOXO-3,4,4A,5-TETRAHYDROBENZO[G]PTERIDIN-10(2H)-YL]PENTYL+DIHYDROGEN+DIPHOSPHATE'>D73</scene><br> | |||
<tr><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[4uv8|4uv8]], [[4uv9|4uv9]], [[4uvb|4uvb]], [[4uvc|4uvc]]</td></tr> | |||
<tr><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4uva FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4uva OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4uva RCSB], [http://www.ebi.ac.uk/pdbsum/4uva PDBsum]</span></td></tr> | |||
<table> | |||
<div style="background-color:#fffaf0;"> | |||
== Publication Abstract from PubMed == | |||
Histone demethylase KDM1A (also known as LSD1) has become an attractive therapeutic target for the treatment of cancer as well as other disorders such as viral infections. We report on the synthesis of compounds derived from the expansion of tranylcypromine as a chemical scaffold for the design of novel demethylase inhibitors. These compounds, which are substituted on the cyclopropyl core moiety, were evaluated for their ability to inhibit KDM1A in vitro as well as to function in cells by modulating the expression of Gfi-1b, a well recognized KDM1A target gene. The molecules were all found to covalently inhibit KDM1A and to become increasingly selective against human monoamine oxidases MAO A and MAO B through the introduction of bulkier substituents on the cyclopropylamine ring. Structural and biochemical analysis of selected trans isomers showed that the two stereoisomers are endowed with similar inhibitory activities against KDM1A, but form different covalent adducts with the FAD co-enzyme. | |||
Synthesis, biological activity and mechanistic insights of 1-substituted cyclopropylamine derivatives: A novel class of irreversible inhibitors of histone demethylase KDM1A.,Vianello P, Botrugno OA, Cappa A, Ciossani G, Dessanti P, Mai A, Mattevi A, Meroni G, Minucci S, Thaler F, Tortorici M, Trifiro P, Valente S, Villa M, Varasi M, Mercurio C Eur J Med Chem. 2014 Aug 27;86C:352-363. doi: 10.1016/j.ejmech.2014.08.068. PMID:25173853<ref>PMID:25173853</ref> | |||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |||
</div> | |||
== References == | |||
<references/> | |||
__TOC__ | |||
</StructureSection> | |||
[[Category: Botrugno, O.]] | |||
[[Category: Cappa, A.]] | |||
[[Category: Ciossani, G.]] | |||
[[Category: Dessanti, P.]] | |||
[[Category: Mai, A.]] | |||
[[Category: Mattevi, A.]] | |||
[[Category: Mercurio, C.]] | |||
[[Category: Meroni, G.]] | |||
[[Category: Minucci, S.]] | |||
[[Category: Thaler, F.]] | |||
[[Category: Tortorici, M.]] | |||
[[Category: Trifiro, P.]] | |||
[[Category: Valente, S.]] | |||
[[Category: Varasi, M.]] | |||
[[Category: Vianello, P.]] | |||
[[Category: Villa, M.]] | |||
[[Category: Covalent inhibitor]] | |||
[[Category: Transcription]] | |||
Revision as of 12:56, 10 September 2014
LSD1(KDM1A)-CoREST in complex with 1-Methyl-Tranylcypromine (1R,2S)LSD1(KDM1A)-CoREST in complex with 1-Methyl-Tranylcypromine (1R,2S)
Structural highlights
Publication Abstract from PubMedHistone demethylase KDM1A (also known as LSD1) has become an attractive therapeutic target for the treatment of cancer as well as other disorders such as viral infections. We report on the synthesis of compounds derived from the expansion of tranylcypromine as a chemical scaffold for the design of novel demethylase inhibitors. These compounds, which are substituted on the cyclopropyl core moiety, were evaluated for their ability to inhibit KDM1A in vitro as well as to function in cells by modulating the expression of Gfi-1b, a well recognized KDM1A target gene. The molecules were all found to covalently inhibit KDM1A and to become increasingly selective against human monoamine oxidases MAO A and MAO B through the introduction of bulkier substituents on the cyclopropylamine ring. Structural and biochemical analysis of selected trans isomers showed that the two stereoisomers are endowed with similar inhibitory activities against KDM1A, but form different covalent adducts with the FAD co-enzyme. Synthesis, biological activity and mechanistic insights of 1-substituted cyclopropylamine derivatives: A novel class of irreversible inhibitors of histone demethylase KDM1A.,Vianello P, Botrugno OA, Cappa A, Ciossani G, Dessanti P, Mai A, Mattevi A, Meroni G, Minucci S, Thaler F, Tortorici M, Trifiro P, Valente S, Villa M, Varasi M, Mercurio C Eur J Med Chem. 2014 Aug 27;86C:352-363. doi: 10.1016/j.ejmech.2014.08.068. PMID:25173853[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. References
|
| ||||||||||||||||||